Abstract:Background Among the several available DMARDs, Methotrexate (MTX) is currently the most widely used drug in clinical practice. About 30-40% of the patients could experience an adequate response to MTX alone; thus, it might not be necessary to start intensive combination therapy for all newly diagnosed RA patients. Given ACR20 response rate of MTX monotherapy is only 46% ∼65%, it is possible that a significant number of early RA patients could suffer from a failure of monotherapy. Therefore, it is important to identify biomarkers predictive of non-response to MTX monotherapy. In the past, using microarray genome-wide analysis of gene expression profile of peripheral blood mononuclear cells (PBMCs), we have discovered a small set of discriminative transcripts between MTX- responsive and MTX-resistant RA patients. In this set, the Haptoglobin (HP, OMIM:140100) expression signal was 5.1 fold increased in MTX resistant RA patients. These observations prompted us to investigate whether serum HP levels are able to predict the efficacy of MTX treatment over a period of 3 months. Objectives To investigate whether serum levels of Haptoglobin (HP) could predict responsiveness to methotrexate (MTX) at the 12th week of treatment in patients with recent-onset RA. Methods A total of 69 patients with newly diagnosed and active RA were treated with MTX (initiated at a dosage of 10 mg/week and increased to 20 mg/week after 4-6 weeks). Clinical variables associated with disease activity were recorded at week 0 and week 12. Levels of HP mRNA in PBMCs and serum levels of circulating HP protein at week 0 and week 12 were determined using Real-time PCR and ELISA, respectively. Results After 12 weeks of MTX treatment, 39.1% (n=27) and 60.9% (n=42) of all 69 evaluable patients were classified as responders or non-responders, respectively, according to the DAS-28-ESR score. The baseline HP mRNA expression in PBMCs from non-responders is significantly higher than those in responders (p<0.05). Similar to mRNA expression, non-responders who had inadequate response to 12 weeks MTX therapy showed significantly elevated HP levels at baseline (369.9±159.8 mg/dl) compared to those in responders (255.3±143.9 mg/dl) (p =0.01). Serum HP levels decreased significantly from 255.3±143.9 mg/dl at baseline to 186.4±108.5 mg/dl at week 12 (p =0.04) in responders, but remained at high levels in non-responders (369.9±159.8 mg/dl at baseline vs. 309.6±183.9 mg/dl at week 12; p=0.71). Conclusions Serum levels of HP might predict response to MTX treatment in recent-onset RA patients. References Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363(9410):675-81 Ranganathan P, Eisen S, Yokoyama WM, McLeod HL. Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann Rheum Dis 2003; 62(1):4-9. Disclosure of Interest None Declared

Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials

Validation of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis and Its Clinical Application in Evidencio

Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic

Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients

Genetic Polymorphism Predicting Methotrexate Efficacy in Chinese Patients with Psoriasis Vulgaris.

Safety and Efficacy of Methotrexate for Chinese Adults with Psoriasis with and Without Psoriatic Arthritis

The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian setting

Methotrexate as single therapy in Crohn's disease: Is its long-term efficacy limited?

Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK

Pharmacokinetic-pharmacodynamic modelling and simulation of methotrexate dosing in patients with rheumatoid arthritis

AB0343 A High Serum Level of Haptoglobin is Associated with the Response of 12 Weeks Methotrexate Therapy in Recent-Onset Rheumatoid Arthritis Patients

Evaluation the Effect of Methotrexate on Psoriasis Based on Specialized Pharmaceutical Education

PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial

Are poor prognostic factors a realistic basis for treatment decisions in patients with rheumatoid arthritis? Lessons from the IMPROVED study

The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis

Preliminary study for predicting better methotrexate efficacy in Japanese patients with rheumatoid arthritis

Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial

Efficacy and Safety of Methotrexate in Psoriasis Vulgaris Long-Term Treatment: A Real-World Observation Study

Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)

Cumulative methotrexate dose is not associated with liver fibrosis in patients with a history of moderate to severe psoriasis

A marriage of two "Methusalem" drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate